-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Downgrades Day One Biopharmaceutical to Neutral, Lowers Price Target to $21.5

Benzinga·03/10/2026 11:01:47
Listen to the news
HC Wainwright & Co. analyst Andres Y. Maldonado downgrades Day One Biopharmaceutical (NASDAQ:DAWN) from Buy to Neutral and lowers the price target from $22 to $21.5.